Guo Haiwei, Jiang Mingyun, Cai Juanjuan, Liu Ruiqi, Yao Weiping, Liang Xiaodong, Zhang Haibo
Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People' s Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Zhejiang Key Laboratory of Precision Medicine Research on Head & Neck Cancer, Hangzhou, China.
Front Oncol. 2024 Nov 15;14:1395787. doi: 10.3389/fonc.2024.1395787. eCollection 2024.
Inflammatory myofibroblastic tumors (IMTs) are rare soft-tissue neoplasms. Accordingly, there is no standardized therapy for unresectable or advanced IMT. Chemotherapy, radiotherapy, and targeted molecular therapy play an important role in unresectable or advanced IMT.
We present a 54-year-old man with a cough and chest distress case report. The thoracic surgeon performed the right upper pulmonary occupying lesion wedge resection and enlarged lymph node excision biopsy. Pathologic diagnosis revealed that the morphology of "right upper lung mass" was considered as Inflammatory Myofibroblastic Tumor (IMT). Radiotherapy was indicated at a high dose: 5400cGy in 27 fractions of 2Gy over 5 weeks were delivered combined with cisplatin. The patient was given a CT/MRI and hematological index every 3 months and experienced no more adverse events. The patient survives with no tumor recurrence as of the last follow-up. Progression-free survival (PFS) exceeded 5 years.
We have reviewed the literature and summarized and discussed the radiotherapy treatment options and challenges for IMT. We first reported high-dose radiotherapy combined with chemotherapy treatment for unresectable IMT. Concurrent radiochemotherapy may be considered an intensive treatment for local progress, local recurrence, and nonresectable IMT patients.
炎性肌纤维母细胞瘤（IMTs）是罕见的软组织肿瘤。因此，对于不可切除或晚期IMT没有标准化的治疗方法。化疗、放疗和靶向分子治疗在不可切除或晚期IMT中发挥着重要作用。
我们报告一例54岁男性咳嗽、胸闷病例。胸外科医生进行了右上肺占位性病变楔形切除术和肿大淋巴结切除活检。病理诊断显示“右上肺肿块”的形态学表现被认为是炎性肌纤维母细胞瘤（IMT）。给予高剂量放疗：在5周内分27次给予5400cGy，每次2Gy，并联合顺铂。每3个月对患者进行一次CT/MRI和血液学指标检查，未再出现不良事件。截至最后一次随访，患者存活且无肿瘤复发。无进展生存期（PFS）超过5年。
我们回顾了文献，总结并讨论了IMT的放疗治疗选择和挑战。我们首次报道了高剂量放疗联合化疗治疗不可切除的IMT。同步放化疗可被认为是针对局部进展、局部复发和不可切除IMT患者的强化治疗。
